1. "A computer evaluation of quantitative algorithms for measuring
detection thresholds of cutaneous sensation." O'Brien, PC;
Dyck, PJ; Kosanke, JL. In Quantification of Neurologic Deficit,
Munsat, TL (ed.). Butterworths, Boston, MA: 197-206.
2. "A 4, 2, and 1 stepping algorithm for quick and accurate
estimation of cutaneous sensation threshold." Dyck PJ; O'Brien,
PC; Kosanke, JL; Gillen, DA; Karnes, JL. Neurology, 43
(1993): 1508-1512. *
3. "A standard test of heat-pain responses using CASE IV." Dyck,
PJ; Zimmerman, IR; Johnson, DM; Gillen, DA; Hokanson, JL; Karnes,
JL; Gruener, G; and O'Brien, PC. Journal of the Neurological
Sciences, 136 (1996): 54-63.
4. "Aldose reductase inhibitors and diabetic neuropathy." Dyck,
PJ. Technical report, American Diabetes Association, 1989.
5. "Approaches to quantitative cutaneous sensory assessment." Dyck,
PJ; O'Brien, PC. In Quantification of Neurologic Deficit,
Munsat, TL (ed.). Butterworths, Boston, MA: chapter 15: 187-195.
6. "Clinical and neuropathological criteria for the diagnosis
and staging of diabetic polyneuropathy." Dyck, PJ; Karnes,
JL; Daube, J.; O'Brien, PC; Service, J. Brain, 108 (1985):
861-880.
7. "Comparison of algorithms of testing for use in automated
evaluation of sensation." Dyck, PJ; Karnes, L; Gillen, DA;
O'Brien, PC; Zimmerman, IR; Johnson, DM. Neurology, 40
(1990): 1607-1613. *
8. "Cool, warm, and heat-pain detection thresholds: Testing
methods and inferences about anatomic distribution of receptors." Dyck
PJ; Zimmerman, IR; Gillen, DA; Johnson, D.; Karnes, JL; O'Brien,
PC. Neurology, 43 (1993): 1500-1508. *
9. "Description of ‘Minnesota Thermal Disks' and normal values
of cutaneous thermal discrimination in man." Dyck, PJ; Curtis,
DJ; Bushek, W. Neurology, 24:4 (1974): 325-330.
10. "Detection, characterization, and staging of polyneuropathy:
assessed in diabetics." Dyck, PJ. Muscle and Nerve,
11 (1988): 21-32. *
11. "Detection thresholds of cutaneous sensation." Dyck
PJ; Karnes, JL; O'Brien, PC. In Diabetic Neuropathy, Dyck
PJ; Thomas, PK; Asbury, A; Winegrad, A; Porte, D (eds.). WB Saunders,
Philadelphia, PA, 1987: chapter 11, 107-121.
12. "Detection thresholds of cutaneous sensation in humans." Dyck
PJ; Karnes, JL; O'Brien, PC; Zimmerman, IR. In Peripheral
Neuropathy, Dyck PJ; Thomas, PK; Lambert, EH; Bunge, R. (eds.).
WB Saunders, Philadelphia, PA, 1984: 1103-1138.
13. "Intradermal recombinant human nerve growth factor induces
pressure allodynia and lowered heat-pain threshold in humans." Dyck,
PJ; Peroutka, S; Rask, C; Burton, E; Baker, MK; Lehman, KA; Gillen,
DA; Hokanson, BA; O'Brien, PC. Neurology, 48
(1997): 501-505. *
14. "Introduction of automated systems to evaluate touch-pressure,
vibration, and thermal cutaneous sensation in man." Dyck,
PJ; Zimmerman, IR; O'Brien, PC; Ness, A; Caskey, Patrick E; Karnes,
JL; Bushek, W. Annals of Neurology, 4 (1978): 502-510.
*
15. "Limitations of quantitative sensory testing when patients
are biased toward a bad outcome." Dyck, PJ; Dyck, PJB; Kennedy,
WR; Kesserwani, H; Melanson, M; Ochoa, J; Shy, M; Stevens, JC;
Suarez, GA; O'Brien, PC. Neurology, 50 (1998): 1213. *
16. "Meaningful degrees of prevention or improvement of nerve
conduction in controlled clinical trials of diabetic neuropathy." Dyck,
PJ; O'Brien, PC. Diabetes Care, 12 (1989): 649-652.
17. "Neuropathy symptom profile in health, motor neuron disease,
diabetic neuropathy, and amyloidosis." Dyck, PJ; Karnes,
JL; O'Brien, PC; Swanson, CJ. Neurology, 36 (1986): 1300-1308.
18. "Neurophysiologic Evaluation and Clinical Trials for Neuromuscular
Diseases." Olney, R. K. Muscle and Nerve, 21 (1998):
1365-1367.
19. "Procedures for setting normal values." O'Brien,
PC; Dyck PJ. Neurology, 45:1 (1995): 17-23. **
20. "Quantitative
sensory testing: A consensus report from the Peripheral Neuropathy
Association." Neurology, 43
(1993): 1050-1052. *
21. "Quantitative Sensory Testing: Methodology, Applications,
and Future Directions." Gruener, G; Dyck PJ. Journal of
Clinical Neurophysiology, 11 (1994): 568-583. *
22. "Recombinant human nerve growth factor and diabetic polyneuropathy." Zochodne,
D; Said, G. Neurology, 51 (1998): 662-663. XX
23. "Recombinant human nerve growth factor in the treatment of
diabetic polyneuropathy." Apfel, SC; Kessler, JA; Adornato,
BT; Litchy, WJ; Sanders, C; Rask, CA; and the NGF Study Group. Neurology, 51 (1998): 695-702. XXX
24. "The Rochester Diabetic Neuropathy Study: Design, criteria
for types of neuropathy, selection bias, and reproducibility of
neuropathic tests." Dyck, PJ; Kratz, KM; Lehman, KA; Karnes,
JL; Melton III, LJ; O'Brien, PC; Litchy, WJ; Windebank, AJ; Smith,
BE; Low, PA; Service, FJ; Rizza, RA; Zimmerman, IR. Neurology,
41 (1991): 799-807. *
25. "Variables influencing neuropathic endpoints: The Rochester
Diabetic Neuropathy Study of Healthy Subjects." Dyck PJ;
Litchy, WJ; Lehman, KA; Hokanson, JL; Low, PA; O'Brien, PC. Neurology,
45 (1995): 1115-1121. *
26. "Vibratory and cooling detection thresholds compared with
other tests in diagnosing and staging diabetic neuropathy." Dyck,
PJ; Bushek, W; Spring, EM; Karnes, JL; Litchy, WJ; O'Brien, PC;
Service, FJ. Diabetes Care, 10 (1987): 432-440. *
27.
Understanding Neuropathy. Dyck, PJ. American Diabetes Assoc. Advanced
Information Series reprint 308, 1986.
28. "Essential Insights On Screening Patients For Neuropathy." Haddad,
J. Podiatry Today on-line, April 2001 issue (http://www.podiatrytoday.com/archive/
pod_200104/pod_200104f4.html).
* Address
reprint requests to Peter J. Dyck, MD, Mayo Clinic, 200 First
St. SW, Rochester, MN 55905.
** Address reprint requests to Peter C. O'Brien, PhD, Mayo Clinic,
200 First St. SW, Rochester, MN 55905.
XX Address reprint requests to Douglas Zochodne, MD, University
of Calgary, Department of Clinical Neurosciences, Room 182A, 3330
Hospital Drive NW, Calgary, AB T2N 4N1, Canada.
XXX Address reprint requests to S. C. Apfel, MD, Kennedy Center,
Room 401, Albert Einstein College of Medicine, 1300 Morris Park
Avenue, Bronx, NY 10461.
RETURN
TO WR MEDICAL HOME